{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:32:25Z","timestamp":1792794745786,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Aryogen Pharmed Company","award":["702806"],"award-info":[{"award-number":["702806"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background\/objective<\/jats:title>\n                <jats:p>Osteoporosis is a global health concern with an increasing prevalence worldwide. Denosumab is an antiresoptive agent that has been\u00a0demonstrated to be effective and safe in osteoporotic patients. This study aimed to compare the efficacy and safety of the\u00a0biosimilar denosumab candidate (Arylia) to the originator product (Prolia\u00ae) in postmenopausal osteoporotic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this randomized, double-blind, active-controlled, noninferiority trial, postmenopausal osteoporotic patients received 60\u00a0mg of subcutaneous Arylia or Prolia\u00ae at months 0, 6, and 12 and were followed up for 18\u00a0months. The primary endpoint was the noninferiority of the biosimilar product to the reference product in the percentage change of bone mineral density (BMD) in 18\u00a0months at the lumbar spine (L<jats:sub>1<\/jats:sub>-L<jats:sub>4<\/jats:sub>), total hip, and femoral neck. The secondary endpoints were safety assessment, the incidence of new vertebral fractures, and the trend of bone turnover markers (BTMs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 190 patients were randomized to receive either biosimilar (<jats:italic>n<\/jats:italic>\u2009=\u200995) or reference (<jats:italic>n<\/jats:italic>\u2009=\u200995) denosumab. In the per-protocol (PP) analysis, the lower limits of the\u00a095% two-sided confidence intervals of the\u00a0difference between Arylia and Prolia\u00ae in increasing BMD were greater than the predetermined noninferiority margin of\u2009\u2212\u20091.78 at the lumbar spine, total hip, and femoral neck sites\u00a0(mean differences [95% CIs] of 0.39 [\u2212\u20091.34 to 2.11], 0.04 [\u2212\u20091.61 to 1.69], and 0.41 [\u2212\u20091.58 to 2.40], respectively). The two products were also comparable in terms of safety, new vertebral fractures, and trend of BTMs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The efficacy of the\u00a0biosimilar denosumab was shown to be noninferior to that of the\u00a0reference denosumab, with a comparable safety profile at 18\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03293108\">NCT03293108<\/jats:ext-link>; Registration date: 2017\u201309-19.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02840-8","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T09:03:52Z","timestamp":1656579832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of the\u00a0biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia\u00ae) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Ahmadreza","family":"Jamshidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Vojdanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Soroush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Akbarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asghar","family":"Hajiabbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mirfeizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Khabbazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamhosein","family":"Alishiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anousheh","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Salimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Shirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza Hatef","family":"Fard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MohammadAli","family":"Nazarinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soosan","family":"Soroosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Anjidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Gharibdoost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"2840_CR1","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3171\/2021.3.FOCUS201049","volume":"50","author":"J-P Bryant","year":"2021","unstructured":"Bryant J-P, Perez-Roman RJ, Burks SS, Wang MY. Antiresorptive and anabolic medications used in the perioperative period of patients with osteoporosis undergoing spine surgery: their impact on the biology of fusion and systematic review of the literature. Neurosurg Focus. 2021;50:E13.","journal-title":"Neurosurg Focus"},{"key":"2840_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46\u201356.","journal-title":"Eur J Rheumatol"},{"key":"2840_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11657-020-00872-8","volume":"16","author":"N Fahimfar","year":"2021","unstructured":"Fahimfar N, Noorali S, Yousefi S, Gharibzadeh S, Shafiee G, Panahi N, et al. Prevalence of osteoporosis among the elderly population of Iran. Arch Osteoporos. 2021;16:16.","journal-title":"Arch Osteoporos"},{"key":"2840_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10195-017-0474-7","volume":"18","author":"U Tarantino","year":"2017","unstructured":"Tarantino U, Iolascon G, Cianferotti L, Masi L, Marcucci G, Giusti F, et al. Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology. J Orthop Traumatol. 2017;18:3\u201336.","journal-title":"J Orthop Traumatol"},{"key":"2840_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M. Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res. 2021;16:533.","journal-title":"J Orthop Surg Res"},{"key":"2840_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21926\/obm.geriatr.2104181","volume":"5","author":"N Jiang","year":"2021","unstructured":"Jiang N, Newton B, Jiang X. An overview of osteoporosis management. OBM Geriatrics. 2021;5:1\u20131.","journal-title":"OBM Geriatrics"},{"key":"2840_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26:1\u201346.","journal-title":"Endocr Pract"},{"key":"2840_CR8","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359\u201381.","journal-title":"Osteoporos Int"},{"key":"2840_CR9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104:1623\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"2840_CR10","first-page":"621","volume":"2","author":"S Dutta","year":"2015","unstructured":"Dutta S. Denosumab-A review of its use in the treatment of postmenopausal osteoporosis. Indo Am J Pharmaceut Sci. 2015;2:621\u20137.","journal-title":"Indo Am J Pharmaceut Sci"},{"key":"2840_CR11","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/bph.15024","volume":"178","author":"BL Langdahl","year":"2021","unstructured":"Langdahl BL. Overview of treatment approaches to osteoporosis. Br J Pharmacol. 2021;178:1891\u2013906.","journal-title":"Br J Pharmacol"},{"key":"2840_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2147\/IJWH.S75681","volume":"7","author":"E Cairoli","year":"2015","unstructured":"Cairoli E, Eller-Vainicher C, Chiodini I. Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence. Int J Womens Health. 2015;7:833\u20139.","journal-title":"Int J Womens Health"},{"key":"2840_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756\u201365.","journal-title":"N Engl J Med"},{"key":"2840_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/jwh.2010.2294","volume":"20","author":"NB Watts","year":"2011","unstructured":"Watts NB. The Fracture Risk Assessment Tool (FRAX\u00ae): applications in clinical practice. J Womens Health (Larchmt). 2011;20:525\u201331.","journal-title":"J Womens Health (Larchmt)"},{"key":"2840_CR15","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2007-2814","volume":"93","author":"HG Bone","year":"2008","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149\u201357.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2840_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2840_CR17","unstructured":"U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03974100. Accessed 23 May 2022."},{"key":"2840_CR18","doi-asserted-by":"publisher","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","volume":"11","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y. Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep. 2021;11:11801.","journal-title":"Sci Rep"},{"key":"2840_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/ijp.IJP_346_19","volume":"53","author":"I Singh","year":"2021","unstructured":"Singh I, Jose V, Patel R, Arora S. Denosumab biosimilar in postmenopausal osteoporotic women: a randomized, assessor-blind, active-controlled clinical trial. Indian J Pharmacol. 2021;53:6\u201312.","journal-title":"Indian J Pharmacol"},{"key":"2840_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100293","volume":"13","author":"Y Hirooka","year":"2020","unstructured":"Hirooka Y, Nozaki Y, Inoue A, Li J, Shiga T, Kishimoto K, et al. Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Bone Rep. 2020;13: 100293.","journal-title":"Bone Rep"},{"key":"2840_CR21","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.2147\/DDDT.S270829","volume":"14","author":"K-L Pang","year":"2020","unstructured":"Pang K-L, Low NY, Chin K-Y. A review on the role of Denosumab in fracture prevention. Drug Des Devel Ther. 2020;14:4029\u201351.","journal-title":"Drug Des Devel Ther"},{"key":"2840_CR22","doi-asserted-by":"publisher","first-page":"8738959","DOI":"10.1155\/2016\/8738959","volume":"2016","author":"A S\u00e1nchez","year":"2016","unstructured":"S\u00e1nchez A, Brun LR, Salerni H, Costanzo PR, Gonz\u00e1lez D, Bagur A, et al. Effect of Denosumab on bone mineral density and markers of bone turnover among postmenopausal women with osteoporosis. J Osteoporos. 2016;2016:8738959.","journal-title":"J Osteoporos"},{"key":"2840_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, Shimizu K, Garc\u00eda-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19:370\u201381.","journal-title":"Lancet Oncol"},{"key":"2840_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1759720X11424220","volume":"3","author":"PD Miller","year":"2011","unstructured":"Miller PD. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis. 2011;3:271\u201382.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2840_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/TCRM.S24239","volume":"8","author":"AD Anastasilakis","year":"2012","unstructured":"Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P. Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag. 2012;8:295\u2013306.","journal-title":"Ther Clin Risk Manag"},{"key":"2840_CR26","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ando.2015.10.009","volume":"76","author":"D Di\u00e9dhiou","year":"2015","unstructured":"Di\u00e9dhiou D, Cuny T, Sarr A, NorouDiop S, Klein M, Weryha G. Efficacy and safety of denosumab for the treatment of osteoporosis: a systematic review. Ann Endocrinol (Paris). 2015;76:650\u20137.","journal-title":"Ann Endocrinol (Paris)"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02840-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02840-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02840-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T09:08:38Z","timestamp":1656580118000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02840-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2840"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02840-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the ethics committees of Tehran University of Medical Sciences (No. IR.TUMS.VCR.REC.1395.1588) and Tabriz University of Medical Sciences (No. IR.TBZMED.REC.1395.758). Written informed consent was obtained from each individual participant involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nassim Anjidani is the head of the medical department of Orchid Pharmed Company, which is in collaboration with AryoGen Pharmed Company with respect to conducting clinical trials. There are no other potential conflicts of interest pertaining to this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}